NDAOPHTHALMICSUSPENSION/DROPS
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
10
Data completeness
6/8 — Strong
INVELTYS (loteprednol etabonate) by Alcon is healing. First approved in 2018.
Drug data last refreshed 4h ago · AI intelligence enriched 10h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INVELTYS (loteprednol etabonate) is a topical ophthalmic corticosteroid suspension approved in 2018 for inflammatory eye conditions. It works by inhibiting prostaglandin production and suppressing the inflammatory cascade, including edema, fibrin deposition, capillary dilation, and leukocyte migration. The drug is indicated for patients requiring anti-inflammatory treatment in the anterior segment of the eye.
$0.003BPart D
Peak6.6 years to LOEProduct is at peak lifecycle with established market presence; commercial team remains focused on market maintenance and physician engagement.
Mechanism of Action
healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. While glucocorticoids are known to bind to and activate the glucocorticoid…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (10)
Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract Surgery
Started Apr 2018
381 enrolled
Inflammation Following Ocular Surgery
Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Started Sep 2014
326 enrolled
InflammationPainCataract
Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation
Started Jan 2013
12 enrolled
Pharmacokinetics
Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%
Started Aug 2011
75 enrolled
Dry Eyes
A Comparison of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate Following Cataract Surgery
Started May 2010
90 enrolled
Intraocular Inflammation
Worked on INVELTYS at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.